MCID: CHR465
MIFTS: 21

Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity

Categories: Gastrointestinal diseases, Genetic diseases, Oral diseases, Rare diseases

Aliases & Classifications for Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity

MalaCards integrated aliases for Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity:

Name: Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity 40 12
Diarrhea 6 40 71
Chronic Diarrhoea Due to Guanylate Cyclase 2c Overactivity 12
Congenital Diarrhoea 6 12
Congenital Diarrhea 6 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060780
ICD10 32 P78.3
UMLS 71 C3553270

Summaries for Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity

Disease Ontology : 12 A congenital diarrhea characterized by mild, early-onset chronic diarrhea that has material basis in heterozygous mutation in the GUCY2C gene on chromosome 12p12.

MalaCards based summary : Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity, also known as diarrhea 6, is related to diarrhea 6 and dysentery. The drugs Acidophilus and Bifidobacterium have been mentioned in the context of this disorder. Affiliated tissues include testes, breast and lung.

Related Diseases for Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity

Diseases in the Diarrhea family:

Diarrhea 6 Diarrhea 9
Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity Inflammatory Diarrhea
Acute Diarrhea Congenital Diarrhea

Diseases related to Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 diarrhea 6 12.7
2 dysentery 9.8
3 diarrhea 9.8

Symptoms & Phenotypes for Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity

Drugs & Therapeutics for Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity

Drugs for Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Acidophilus
2 Bifidobacterium

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Clinical Efficacy of Probiotic Bacteria in Subjects With Irritable Bowel Syndrome (IBS), Functional Diarrhea, or Functional Bloating Completed NCT00618904
2 Clinical Utility of Carbohydrate Breath Tests in Unexplained GI Symptoms Completed NCT03261856
3 Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV Completed NCT04165200
4 Efficacy of GB Mixed Full Strength Rice Suji, and Full Strength Rice Suji Alone Compared to 3/4th Strength Rice Suji in the Management of PD in Children Aged > 6 Months to 36 Months: an Open-labeled Randomized Controlled Clinical Trial Recruiting NCT03366740

Search NIH Clinical Center for Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity

Genetic Tests for Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity

Anatomical Context for Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity

MalaCards organs/tissues related to Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity:

40
Testes, Breast, Lung, Bone, Small Intestine, Colon, Liver

Publications for Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity

Articles related to Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity:

(show top 50) (show all 126)
# Title Authors PMID Year
1
Use of ketogenic diet therapy in infants with epilepsy: A systematic review and meta-analysis. 61
32452537 2020
2
Phase I Study of Alternate-Day Administration of S-1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer. 61
32490554 2020
3
A Phase II Trial of Cabozantinib in Hormone Receptor-Positive Breast Cancer with Bone Metastases. 61
32463152 2020
4
Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. 61
32303539 2020
5
A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. 61
31941830 2020
6
Oral Vancomycin May Be Associated With Earlier Symptom Resolution Than Metronidazole for Hospitalized Children With Nonsevere Clostridiodes difficile Infections. 61
31950069 2019
7
Lymphocytic esophagitis: An Australian (Queensland) case series of a newly recognized mimic of eosinophilic esophagitis. 61
31633045 2019
8
Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer. 61
30603911 2019
9
Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial. 61
30833272 2019
10
[Efficacy and safety of vandetanib on advanced medullary thyroid carcinoma: single center result from a phase Ⅲ study]. 61
31262109 2019
11
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. 61
31230047 2019
12
Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. 61
30179569 2018
13
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer. 61
29334603 2018
14
A comparative analysis of quality of life after postoperative intensity-modulated radiotherapy or three-dimensional conformal radiotherapy for cervical cancer. 61
30829265 2018
15
Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents. 61
29891609 2018
16
Enterotoxigenic Escherichia coli Adhesin-Toxoid Multiepitope Fusion Antigen CFA/I/II/IV-3xSTaN12S-mnLTG192G/L211A-Derived Antibodies Inhibit Adherence of Seven Adhesins, Neutralize Enterotoxicity of LT and STa Toxins, and Protect Piglets against Diarrhea. 61
29263112 2018
17
A Case of Mesenteric Cyst in a 4-Year-Old Child with Acute Abdominal Pain. 61
29302510 2017
18
Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes. 61
27858180 2017
19
A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. 61
28109627 2017
20
Optimization of a Scoring System to Predict Microscopic Colitis in a Cohort of Patients With Chronic Diarrhea. 61
27404403 2017
21
Cobimetinib. 61
27701080 2017
22
A phase I study of oral UFT/leucovorin and irinotecan, plus radiation for locally recurrent rectal cancer. 61
31583301 2017
23
Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study). 61
26778644 2016
24
The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis. 61
27003816 2016
25
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. 61
26598548 2016
26
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study). 61
26642810 2016
27
Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction. 61
26499900 2015
28
Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. 61
25822310 2015
29
A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors. 61
25371323 2015
30
[Association of UGT1A1 (*28, *60 and * 93) polymorphism with the adverse reactions of irinotecan chemotherapy in extensive stage small cell lung cancer]. 61
25877315 2015
31
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. 61
25037971 2015
32
DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. 61
25320100 2014
33
Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO). 61
24112786 2014
34
Non-polio enterovirus association with persistent diarrhea in children as revealed by a follow-up study of an Indian cohort during the first two years of life. 61
24954472 2014
35
Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture. 61
24849768 2014
36
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. 61
24615777 2014
37
Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study. 61
24799054 2014
38
[Efficacy and safety of combination of sorafenib and transarterial chemoembolization in treating primary hepatocellular carcinoma]. 61
24581125 2014
39
A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group. 61
23111359 2014
40
[Status of enterovirus infection in children with acute lower respiratory tract infection]. 61
23676941 2013
41
UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer. 61
22934695 2013
42
Relative effectiveness and safety of chemotherapy in elderly and nonelderly patients with stage III colon cancer: a systematic review. 61
23299774 2013
43
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study. 61
23838576 2013
44
Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy. 61
23060583 2012
45
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). 61
22634799 2012
46
Teething disturbances; prevalence of objective manifestations in children under age 4 months to 36 months. 61
22143712 2012
47
A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine. 61
21626051 2012
48
What palliative care-related problems do patients experience at HIV diagnosis? A systematic review of the evidence. 61
21620647 2011
49
Systematic review of health-related quality of life after esophagectomy for esophageal cancer. 61
22180708 2011
50
Adjuvant chemoradiation for resected gastric cancer: a 10-year experience. 61
21327926 2011

Variations for Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity

Expression for Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity

Search GEO for disease gene expression data for Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity.

Pathways for Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity

GO Terms for Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity

Sources for Chronic Diarrhea Due to Guanylate Cyclase 2c Overactivity

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....